PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
24059944-8	2013	After adjusting for baseline differences, fingolimod was associated with a 52% reduction in the probability of having a relapse (odds ratio, 0.48; 95% confidence interval [CI], 0.28-0.84; p = 0.0097) and a 50% reduction in ARR (rate ratio, 0.50; 95% CI, 0.34-0.75; p = 0.0006) compared with IFN/GA.	Fingolimod Hydrochloride	42-52	interferon alpha 1	Homo sapiens	291-297	
26111826-8	2016	After switching to fingolimod (M0-12 vs M13-EOS), patients initially treated with IFN had a 50% reduction in ARR (0.40 vs 0.20), reduced MRI activity and a lower rate of brain volume loss.	Fingolimod Hydrochloride	19-29	interferon alpha 1	Homo sapiens	82-85	
26111826-9	2016	In a post hoc analysis, the proportion of IFN-switch patients with no evidence of disease activity increased by approximately 50% in the first year after switching to fingolimod treatment (44.3% to 66.0%).	Fingolimod Hydrochloride	167-177	interferon alpha 1	Homo sapiens	42-45	
29854416-7	2018	Regardless of age, fingolimod-treated patients were more likely to achieve NEDA-3 versus placebo/IFN beta-1a, with strongest benefits in the youngest patients (all p < 0.05).	Fingolimod Hydrochloride	19-29	interferon alpha 1	Homo sapiens	97-100